To determine this, tumor samples were sequenced to quantify shRNA constructs which were absent and present, comparing between the isotype control and anti-PD-1-treated groups, with a goal of identifying genes that are preferentially lost in the anti-PD-1-treated21. This evidence concerns the gene PDCD1 and neoplasm.